iScience (Feb 2023)
Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region
- Marc Emmenegger,
- Elena De Cecco,
- David Lamparter,
- Raphaël P.B. Jacquat,
- Julien Riou,
- Dominik Menges,
- Tala Ballouz,
- Daniel Ebner,
- Matthias M. Schneider,
- Itzel Condado Morales,
- Berre Doğançay,
- Jingjing Guo,
- Anne Wiedmer,
- Julie Domange,
- Marigona Imeri,
- Rita Moos,
- Chryssa Zografou,
- Leyla Batkitar,
- Lidia Madrigal,
- Dezirae Schneider,
- Chiara Trevisan,
- Andres Gonzalez-Guerra,
- Alessandra Carrella,
- Irina L. Dubach,
- Catherine K. Xu,
- Georg Meisl,
- Vasilis Kosmoliaptsis,
- Tomas Malinauskas,
- Nicola Burgess-Brown,
- Ray Owens,
- Stephanie Hatch,
- Juthathip Mongkolsapaya,
- Gavin R. Screaton,
- Katharina Schubert,
- John D. Huck,
- Feimei Liu,
- Florence Pojer,
- Kelvin Lau,
- David Hacker,
- Elsbeth Probst-Müller,
- Carlo Cervia,
- Jakob Nilsson,
- Onur Boyman,
- Lanja Saleh,
- Katharina Spanaus,
- Arnold von Eckardstein,
- Dominik J. Schaer,
- Nenad Ban,
- Ching-Ju Tsai,
- Jacopo Marino,
- Gebhard F.X. Schertler,
- Nadine Ebert,
- Volker Thiel,
- Jochen Gottschalk,
- Beat M. Frey,
- Regina R. Reimann,
- Simone Hornemann,
- Aaron M. Ring,
- Tuomas P.J. Knowles,
- Milo A. Puhan,
- Christian L. Althaus,
- Ioannis Xenarios,
- David I. Stuart,
- Adriano Aguzzi
Affiliations
- Marc Emmenegger
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland; Corresponding author
- Elena De Cecco
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland
- David Lamparter
- Health2030 Genome Center, 9 Chemin des Mines, 1202 Geneva, Switzerland
- Raphaël P.B. Jacquat
- Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK; Cavendish Laboratory, Department of Physics, University of Cambridge, JJ Thomson Avenue, Cambridge CB3 0HE, UK
- Julien Riou
- Institute of Social and Preventive Medicine, University of Bern, 3012 Bern, Switzerland
- Dominik Menges
- Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zürich, Switzerland
- Tala Ballouz
- Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zürich, Switzerland
- Daniel Ebner
- Target Discovery Institute, University of Oxford, Oxford OX3 7FZ, England
- Matthias M. Schneider
- Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK
- Itzel Condado Morales
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland
- Berre Doğançay
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland
- Jingjing Guo
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland
- Anne Wiedmer
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland
- Julie Domange
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland
- Marigona Imeri
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland
- Rita Moos
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland
- Chryssa Zografou
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland
- Leyla Batkitar
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland
- Lidia Madrigal
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland
- Dezirae Schneider
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland
- Chiara Trevisan
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland
- Andres Gonzalez-Guerra
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland
- Alessandra Carrella
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland
- Irina L. Dubach
- Division of Internal Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
- Catherine K. Xu
- Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK
- Georg Meisl
- Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK
- Vasilis Kosmoliaptsis
- Department of Surgery, Addenbrooke’s Hospital, University of Cambridge, Hills Road, Cambridge CB2 0QQ, UK; NIHR Blood and Transplant Research Unit in Organ Donation and Transplantation, University of Cambridge, Hills Road, Cambridge CB2 0QQ, UK
- Tomas Malinauskas
- Division of Structural Biology, The Wellcome Centre for Human Genetics, University of Oxford, Headington, Oxford OX3 7BN, UK
- Nicola Burgess-Brown
- Structural Genomics Consortium, University of Oxford, Oxford OX3 7DQ, UK
- Ray Owens
- Division of Structural Biology, The Wellcome Centre for Human Genetics, University of Oxford, Headington, Oxford OX3 7BN, UK; The Rosalind Franklin Institute, Harwell Campus, Oxford OX11 0FA, UK
- Stephanie Hatch
- Target Discovery Institute, University of Oxford, Oxford OX3 7FZ, England
- Juthathip Mongkolsapaya
- Nuffield Department of Medicine, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
- Gavin R. Screaton
- Nuffield Department of Medicine, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
- Katharina Schubert
- Department of Biology, Institute of Molecular Biology and Biophysics, ETH Zurich, Zurich, Switzerland
- John D. Huck
- Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA
- Feimei Liu
- Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA
- Florence Pojer
- Protein Production and Structure Core Facility, EPFL SV PTECH PTPSP, 1015 Lausanne, Switzerland
- Kelvin Lau
- Protein Production and Structure Core Facility, EPFL SV PTECH PTPSP, 1015 Lausanne, Switzerland
- David Hacker
- Protein Production and Structure Core Facility, EPFL SV PTECH PTPSP, 1015 Lausanne, Switzerland
- Elsbeth Probst-Müller
- Department of Immunology, University Hospital Zurich, 8091 Zurich, Switzerland
- Carlo Cervia
- Department of Immunology, University Hospital Zurich, 8091 Zurich, Switzerland
- Jakob Nilsson
- Department of Immunology, University Hospital Zurich, 8091 Zurich, Switzerland
- Onur Boyman
- Department of Immunology, University Hospital Zurich, 8091 Zurich, Switzerland; Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland
- Lanja Saleh
- Institute of Clinical Chemistry, University Hospital Zurich, 8091 Zurich, Switzerland
- Katharina Spanaus
- Institute of Clinical Chemistry, University Hospital Zurich, 8091 Zurich, Switzerland
- Arnold von Eckardstein
- Institute of Clinical Chemistry, University Hospital Zurich, 8091 Zurich, Switzerland
- Dominik J. Schaer
- Division of Internal Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
- Nenad Ban
- Department of Biology, Institute of Molecular Biology and Biophysics, ETH Zurich, Zurich, Switzerland
- Ching-Ju Tsai
- Department of Biology and Chemistry, Laboratory of Biomolecular Research, Paul Scherrer Institute, 5303 Villigen-PSI, Switzerland
- Jacopo Marino
- Department of Biology and Chemistry, Laboratory of Biomolecular Research, Paul Scherrer Institute, 5303 Villigen-PSI, Switzerland
- Gebhard F.X. Schertler
- Department of Biology and Chemistry, Laboratory of Biomolecular Research, Paul Scherrer Institute, 5303 Villigen-PSI, Switzerland; Department of Biology, ETH Zürich, 8093 Zürich, Switzerland
- Nadine Ebert
- Institute of Virology and Immunology, 3012 Bern, Switzerland; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland
- Volker Thiel
- Institute of Virology and Immunology, 3012 Bern, Switzerland; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland
- Jochen Gottschalk
- Regional Blood Transfusion Service Zurich, Swiss Red Cross, 8952 Schlieren, Switzerland
- Beat M. Frey
- Regional Blood Transfusion Service Zurich, Swiss Red Cross, 8952 Schlieren, Switzerland
- Regina R. Reimann
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland
- Simone Hornemann
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland
- Aaron M. Ring
- Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA
- Tuomas P.J. Knowles
- Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK; Cavendish Laboratory, Department of Physics, University of Cambridge, JJ Thomson Avenue, Cambridge CB3 0HE, UK
- Milo A. Puhan
- Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zürich, Switzerland
- Christian L. Althaus
- Institute of Social and Preventive Medicine, University of Bern, 3012 Bern, Switzerland
- Ioannis Xenarios
- Health2030 Genome Center, 9 Chemin des Mines, 1202 Geneva, Switzerland; Agora Center, University of Lausanne, 25 Avenue du Bugnon, 1005 Lausanne, Switzerland
- David I. Stuart
- Division of Structural Biology, The Wellcome Centre for Human Genetics, University of Oxford, Headington, Oxford OX3 7BN, UK
- Adriano Aguzzi
- Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland; Corresponding author
- Journal volume & issue
-
Vol. 26,
no. 2
p. 105928
Abstract
Summary: Effective public health measures against SARS-CoV-2 require granular knowledge of population-level immune responses. We developed a Tripartite Automated Blood Immunoassay (TRABI) to assess the IgG response against three SARS-CoV-2 proteins. We used TRABI for continuous seromonitoring of hospital patients and blood donors (n = 72′250) in the canton of Zurich from December 2019 to December 2020 (pre-vaccine period). We found that antibodies waned with a half-life of 75 days, whereas the cumulative incidence rose from 2.3% in June 2020 to 12.2% in mid-December 2020. A follow-up health survey indicated that about 10% of patients infected with wildtype SARS-CoV-2 sustained some symptoms at least twelve months post COVID-19. Crucially, we found no evidence of a difference in long-term complications between those whose infection was symptomatic and those with asymptomatic acute infection. The cohort of asymptomatic SARS-CoV-2-infected subjects represents a resource for the study of chronic and possibly unexpected sequelae.
